Aclot Pharma SRL
2.5 FTEAclot Pharma reported total assets of €1.22m at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Sep 2026), with 2.5 full-time equivalents.
The score of Aclot Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets -15 % Headcount (avg FTE) -7 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Aclot Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Sep 2026
- Year ended 31 Dec 2024filed on 04 Jul 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 28 Jul 2023
- Year ended 31 Dec 2021filed on 27 Jul 2022
Aclot Pharma's financial analysis
- Solvency10.4%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Aclot Pharma
Aclot Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0456.857.330
- VAT number
- BE0456857330
- Peppol
- Registered · 0208:0456857330 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 20 Dec 1995
- Registered office
- 1400 Nivelles
- Size
- Micro · 2.5 FTE
- Latest accounts
- 2025 · filed on 27 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Aclot Pharma (SRL) has been based in Nivelles since 1995, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 107 € and equity of 126,895 €; its revenue is not published. With 2.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 10.4%, below the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Aclot Pharma
Companies in the same business, of comparable size and area, outside its group.
- Langenaken Retail sale of pharmaceutical products Bilzen-Hoeselt · balance sheet €1.22m
- Pharma Beart Retail sale of pharmaceutical products Manage · balance sheet €1.22m
- Vandenabeele-Hungenaert Retail sale of pharmaceutical products Damme · balance sheet €1.23m
- Apoteek Van Bulck Retail sale of pharmaceutical products Beringen · balance sheet €1.22m
- Apotheek Reymen Retail sale of pharmaceutical products Laakdal · balance sheet €1.22m
- PHARMACIE Charleroi Nord Retail sale of pharmaceutical products Charleroi · balance sheet €1.22m
- Cynara Retail sale of pharmaceutical products Brussels · balance sheet €1.22m
- Niemegeers-Engels BV Retail sale of pharmaceutical products Asse · balance sheet €1.23m
Frequently asked questions about Aclot Pharma
What is the revenue of Aclot Pharma?
Aclot Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Aclot Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0456857330 for Aclot Pharma, if the company is VAT-registered. Its company number (CBE) is 0456.857.330.
Where is the registered office of Aclot Pharma?
According to the CBE register, the registered office of Aclot Pharma is in 1400 Nivelles.
What is the equity of Aclot Pharma?
At the close of the 2025 financial year, the equity of Aclot Pharma amounts to 126,895 €, a solvency of 10.4% of total assets.
How many people work at Aclot Pharma?
2.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Aclot Pharma?
The register lists 2 active mandates at Aclot Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Aclot Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →